the European Institute of Oncology
Published by:
The 33rd European Society for Medical Oncology Congress
Stockholm, 12-16th September 2008
Watch Press Conferences from ESMO 2008
Accompanying slides coming soon
Official 33rd ESMO Press Conference - 13th September 2008
Adobe Flash player is required to view ecancer.tv
ecancer.tv
Prof. Martine Piccart, EORTC President: Calls for greater cancer drug funding from governments and emphasises targeted therapy.
ecancer.tv
Prof. José Baselga, ESMO President: Discusses the conference's 'practice changing data' and the upcoming 'tremendous cancer burden'.
ecancer.tv
Prof. Vincent Gregoire, ESTRO President: Discusses a multidisciplinary approach to cancer.
ecancer.tv
Prof. Irving Taylor, ESSO President: Quality surgery, radiotherapy and medical oncology working together.
ecancer.tv
Prof. Rafael Rosell, Spanish Lung Cancer Group: Benefits of customising erlotinib therapy for NSCLC.
Official 33rd ESMO Press Conference - 14th September 2008
Adobe Flash player is required to view ecancer.tv
ecancer.tv
Dr Marco Merlano, S. Croce General Hospital: Chemotherapy, radiotherapy and cetuximab in head and neck cancer.
Official 33rd ESMO Press Conference - 15th September 2008
Adobe Flash player is required to view ecancer.tv
ecancer.tv
Dr. Francesco Cognetti, Istituto Oncologia Regina Elena, Italy: Taxotere with chemo improves survival in early breast cancer.
ecancer.tv
Dr. Michael Auerbach, Haematologist, Baltimore, USA: Intravenous iron improves treatment response in cancer-related anemia.
ecancer.tv
Prof. Nasser Altorki, Cornell University, New York: Novel trial of pazopanib before early stage lung cancer surgery
ecancer.tv
Prof. Michael Friedlander, Prince of Wales Hospital, Australia: Investigational drug shows promise in ovarian cancer.
ecancer.tv
Dr. Nils Wilking, Karolinska Institute, Sweden: European disparities in access to cancer drugs.
ecancer.tv
Prof. Tony Mok, Chinese University, Hong Kong: Gefitinib for asian non-smokers with lung cancer.
ecancer.tv
Prof. Bradley Monk, University of California Irvine Medical Center: Promising new treatment option for women with recurrent ovarian cancer.
ecancer.tv
Raquel Catarino, Portuguese Institute of Oncology: Gene variant increases melanoma risk.
ecancer.tv
Prof. Poulam Patel, Nottingham University, UK: Extended, escalated dose chemo shows no survival benefit in advanced melanoma.
Official 33rd ESMO Press Conference - 16th September 2008
Adobe Flash player is required to view ecancer.tv
ecancer.tv
Prof. Matthias Löhr, Karolinska Institute, Sweden: New drug substantially extends survival in pancreatic cancer.
ecancer.tv
Prof. Michael Gnant, Medical University of Vienna: Zoledronic acid added to adjuvant endocrine therapy prevents pre-menopausal breast cancer recurrences.
ecancer.tv
Prof. Eric Van Cutsem, University Hospital Gasthuisberg: K-Ras mutations and FOLFIRI plus cetuximab in mCRC.
ecancer.tv
Dr. Christos Karapetis, Flinders University, Australia: Gene marker indicates doubling of survival time in cetuximab-treated CRC.
